DARIC33 CAR T-cells in AML

admin_vjr_user — Thu, 12 Aug 2021 10:07:39 +0000

Jacob Appelbaum, MD, PhD, University of Washington, Seattle, WA, describes pre-clinical research investigating dimerizing agent regulated immunoreceptor complex targeting CD33 (DARIC33) chimeric antigen receptor (CAR) T-cells for the treatment of acute myeloid leukemia (AML). This study demonstrated the ability to pharmacologically control the anti-CD33 activity of DARIC33 T cells through the pulsatile dosing of rapamycin, as well as the ability to modulate anti-tumor activity of DARIC33 T cells using rapamycin in a mouse model. The superior control that DARIC33 provides over CAR-T cells may facilitate the development of more broadly applicable and potent CAR T-cell therapies, using multiplex targeting technology and potency enhancement. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

DARIC33: CAR T with an on/off switch

admin_vjr_user — Thu, 03 Jun 2021 16:50:53 +0000

Jacob Appelbaum, MD, PhD, University of Washington, Seattle, WA, describes the mechanism of action of dimerizing agent regulated immunoreceptor complex targeting CD33 (DARIC33) technology, a bioengineered T cell therapy currently being investigated for acute myeloid leukemia (AML). In DARIC33, the T cell signaling and antigen binding domains of a chimeric antigen receptor (CAR) are separated and a heterodimerizing unit responsive to rapamycin (RAPA) is embedded, allowing the anti-AML activity of the CAR T cell to be turned on and off in response to RAPA. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

DARIC33 – VJRegenMed

DARIC33 CAR T-cells in AML

DARIC33: CAR T with an on/off switch